Healthcare >> CEO Interviews >> October 12, 2001
JAMES A. SCHOENECK joined Prometheus Laboratories Inc. in December 1999
as President and Chief Operating Officer. In April 2000 he was appointed
President and Chief Executive Officer of the company. Prior to joining
Prometheus, Mr. Schoeneck was Vice President and General Manager,
Immunology Business Unit of Centocor, Inc., a division of Johnson &
Johnson. His responsibilities included leading all aspects of Centocor's
Immunology Business Unit on a worldwide basis, including a strategic
partnership with Schering-Plough Corporation. Before that assignment,
Mr. Schoeneck served as Centocor's Vice President of Marketing and
Commercial Development, re-establishing the company's direct commercial
infrastructure and overseeing partnerships with Eli Lilly and Glaxo
Wellcome. Prior to Centocor, he spent 13 years at Rhne-Poulenc Rorer,
Inc. in various sales and marketing positions, including Director of
Healthcare Services, Director of Marketing, Group Product Director,
Product Manager, Senior Area Sales Manager and Specialty Sales
Representative. Mr. Schoeneck also served for three years as volunteer
President of the Board of the Asthma and Allergy Foundation of America. Profile
Laboratories, Inc?
Mr. Schoeneck: Prometheus is a privately held specialty pharmaceutical
company that acquires, develops and
